23andMe Holding Co (ME)
0.5971
+0.01
(+2.07%)
USD |
NASDAQ |
May 16, 16:00
0.5972
0.00 (0.00%)
After-Hours: 20:00
23andMe Revenue (Quarterly): 44.75M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 44.75M |
| September 30, 2023 | 50.00M |
| June 30, 2023 | 60.86M |
| March 31, 2023 | 92.38M |
| December 31, 2022 | 66.94M |
| September 30, 2022 | 75.66M |
| June 30, 2022 | 64.51M |
| March 31, 2022 | 100.56M |
| Date | Value |
|---|---|
| December 31, 2021 | 56.89M |
| September 30, 2021 | 55.20M |
| June 30, 2021 | 59.24M |
| March 31, 2021 | 88.58M |
| December 31, 2020 | 55.48M |
| September 30, 2020 | 51.80M |
| June 30, 2020 | 48.06M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
44.75M
Minimum
Dec 2023
100.56M
Maximum
Mar 2022
64.73M
Average
59.24M
Median
Jun 2021
Revenue (Quarterly) Benchmarks
| RadNet Inc | 431.71M |
| DermTech Inc | 3.924M |
| iSpecimen Inc | 2.29M |
| Sera Prognostics Inc | -- |
| Progyny Inc | 278.08M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -277.98M |
| Total Expenses (Quarterly) | 125.66M |
| EPS Diluted (Quarterly) | -0.58 |
| Enterprise Value | 45.93M |
| Gross Profit Margin (Quarterly) | 44.55% |
| Profit Margin (Quarterly) | -621.2% |
| Earnings Yield | -185.9% |
| Normalized Earnings Yield | -128.51 |